Specifically, our model simultaneously predicts critical glioma biomarkers including IDH mutation, 1p/19q co-deletion, MGMT promoter methylation, and WHO tumor grade (II, III, IV), while precisely delineating the tumor's T2-weighted hyperintense region. This evidence concerns the gene MGMT and central nervous system cancer.